Part E. General Provisions Relating to Drugs and Devices
Index
- 21 U.S.C. § 360bbb Expanded Access to Unapproved Therapies and Diagnostics
- 21 U.S.C. § 360bbb-0 Expanded Access Policy Required For Investigational Drugs
- 21 U.S.C. § 360bbb-0a Investigational Drugs For Use By Eligible Patients
- 21 U.S.C. § 360bbb-1 Dispute Resolution
- 21 U.S.C. § 360bbb-2 Classification of Products
- 21 U.S.C. § 360bbb-3 Authorization For Medical Products For Use In Emergencies
- 21 U.S.C. § 360bbb-3a Emergency Use of Medical Products
- 21 U.S.C. § 360bbb-3b Products Held For Emergency Use
- 21 U.S.C. § 360bbb-3c Expedited Development and Review of Medical Products For Emergency Uses
- 21 U.S.C. § 360bbb-4 Countermeasure Development, Review, and Technical Assistance
- 21 U.S.C. § 360bbb-4a Priority Review to Encourage Treatments For Agents that Present National Security Threats
- 21 U.S.C. § 360bbb-4b Medical Countermeasure Master Files
- 21 U.S.C. § 360bbb-5 Critical Path Public-Private Partnerships
- 21 U.S.C. § 360bbb-5a Emerging Technology Program
- 21 U.S.C. § 360bbb-6 Risk Communication
- 21 U.S.C. § 360bbb-7 Notification
- 21 U.S.C. § 360bbb-8 Consultation With External Experts On Rare Diseases, Targeted Therapies, and Genetic Targeting of Treatments
- 21 U.S.C. § 360bbb-8a Optimizing Global Clinical Trials
- 21 U.S.C. § 360bbb-8b Use of Clinical Investigation Data From Outside the United States
- 21 U.S.C. § 360bbb-8c Patient Participation In Medical Product Discussion
- 21 U.S.C. § 360bbb-8d Notification, Nondistribution, and Recall of Controlled Substances